Funding profile · Immuno-oncology platform

Granza Bio

A preclinical biotech that closed an oversubscribed $7.14 million seed round in July 2024, on top of a $500,000 Y Combinator investment. No Form D or other SEC filing for either Granza Bio entity was found on record as of this profile.

$7.64MTotal raised to date, by third party trackers (PitchBook, Tracxn)
$7.14MSeed round closed Jul 3, 2024, company reported as oversubscribed
$500KY Combinator accelerator investment, Apr 2024
0SEC Form D filings found for Granza Bio, Inc. or Granza Bio Corporation

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Jan 2024 UK entity incorporated GBP 1 statement of capital Founders UK filing
Apr 2024 Y Combinator, Winter 2024 batch $500,000 Y Combinator Tracker data
Jul 3, 2024 Seed, oversubscribed $7.14M Led by Felicis and Refactor. Participation from Y Combinator, Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, North South Ventures, and named angels including several former YC partners Company release
Since Jul 2024 Series A or later None reported None announced Not found

What the filings show

No Form D notice appears on SEC EDGAR for Granza Bio, Inc., Granza Bio Corporation, or any obvious variant of the name, in the searches run for this profile. That is consistent with the company’s own records file, which lists no Form D and no EDGAR mentions for Granza Bio. Two entities do have a public filing trail outside the SEC. Granza Bio Corporation is a Delaware stock corporation registered to do business in California, filed with the California Secretary of State on July 29, 2024, document number 6324794, address 95 Third Street, San Francisco. Ashwin Nandakumar is listed as chief executive officer, chief financial officer and a director; Ashwin Jainarayanan is listed as secretary and a director. Granza Bio Limited was incorporated in the UK on January 19, 2024, with a GBP 1 statement of capital, and its registered office moved from a London address to Oxford’s Bioescalator incubator in January 2025. Its UK filings to date are routine: confirmation statements and micro-company accounts, which do not disclose revenue or share allotments in detail.

Reading the money

  1. A round can close without a Form D showing up.Companies raising under the Section 4(a)(2) exemption, rather than Regulation D, are not required to file a Form D at all, and a filing can also simply lag. The absence of a filing here does not mean the reported $7.14 million did not close, only that it has not left a matching SEC record as of this profile.
  2. The two published totals are compatible, not competing.TechCrunch and the company’s own release describe a $7.14 million seed. Tracxn’s $7.64 million figure for total funding adds in a separate $500,000 Y Combinator investment from April 2024, ahead of the seed. Read together they describe one continuous raise, not two conflicting numbers.
  3. The investor list traces back to Y Combinator’s network.Several of the named angels in the July 2024 release are identified as former YC Group Partners or Visiting Group Partners, and the round’s lead investors both worked with the company through its YC batch. That fits the founders’ own account of being introduced to fundraising through YC’s biotech partner.
  4. One third party estimate does not hold up.GetLatka’s profile of Granza Bio states the company had reached $5 million in revenue by June 2024, a month before the seed round it also says never happened, and gives 2023 as the founding year against a 2024 date confirmed by both the California and UK filings. Treat that revenue figure as an unverified automated estimate, not a reported number.
  5. The corporate structure spans two countries.A Delaware corporation doing business in California sits alongside a UK limited company registered at Oxford’s Bioescalator, the university’s life sciences incubator. That mirrors the founding story: research and academic roots at Oxford, commercialization and fundraising built around Y Combinator in San Francisco.

Commercial signals

Signal Detail Source type
Regulatory No FDA or IND-related filing found. Preclinical stage. Not found
Platform data November 2025 bioRxiv preprint reports purified attack particles slowing tumor growth in mouse melanoma and pancreatic cancer models. Not peer reviewed. Co-founders Jainarayanan and Dustin disclose their Granza Bio equity interest in the paper itself. Public record
Investor quality Lead investors Felicis and Refactor are established venture firms; Felicis has backed Ginkgo Bioworks and Recursion Pharmaceuticals in life sciences. Independent
Conference presence CEO Ashwin Nandakumar listed to present at Cell & Gene Meeting on the Mesa, October 6, 2026, a closely watched cell and gene therapy investor conference. Independent
Team size Reported as 8 by Y Combinator, 7 by PitchBook, and 6 by GetLatka at different points, a range consistent with a small preclinical team rather than a specific conflict. Tracker data

What to watch

  • Whether a Form D or other SEC filing appears for either Granza entity.
  • A named Series A round following the 2024 seed.
  • Peer review outcome for the November 2025 SMAP isolation preprint.
  • Any licensing or pharma partnership announcement, none of which has been reported to date.

The Granza Bio story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • SFA Therapeutics: Shared investor: North South Ventures. A Temple University spinout turning short chain fatty acids from the human gut into oral pills
  • dNovo: Shared investor: Felicis. A Stanford trained biologist's direct reprogramming system once grew human hair on the backs of lab mice
  • YourChoice Therapeutics: Shared investor: North South Ventures. A San Francisco company developing YCT-529, an oral non-hormonal male contraceptive licensed from the University of Minnesota
  • Parallel Bio: Shared investor: Refactor. Miniature human lymph nodes, grown from donated tissue and run side by side across hundreds of donors, used to test drugs and vaccines before anyone takes them

Sources

  1. CompanyGranza Bio Raises $7M+ Seed Funding to Advance the Delivery of Cancer Treatment and Genetic MedicinesPR Newswire, via BioSpace · Jul 10, 2024
  2. IndependentGranza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatmentsTechCrunch, Marina Temkin · Jul 3, 2024
  3. IndependentGranza Bio 2026 Company Profile: Valuation, Funding & InvestorsPitchBook · accessed Sep 25, 2026
  4. IndependentGranza Bio Funding Rounds & List of InvestorsTracxn · accessed Sep 25, 2026
  5. Public recordGranza Bio Corporation, California filing recordCalifornia Secretary of State via bizprofile.net · filed Jul 29, 2024
  6. Public recordGranza Bio Limited, company overview and filing historyUK Companies House · incorporated Jan 19, 2024
  7. Public recordJainarayanan et al., Isolation of functional supramolecular attack particles (SMAPs)bioRxiv preprint · Nov 12, 2025
  8. UnreliableGranza Bio Revenue 2024: $5M Est. ARRGetLatka · accessed Sep 25, 2026
  9. CompanyGranza Bio company page and launch postY Combinator · accessed Sep 25, 2026
  10. CompanyGranza Bio company presentationCell & Gene Meeting on the Mesa · Oct 6, 2026 listing, accessed Aug 19, 2026

Compiled from California and UK corporate filings and published reports as of September 25, 2026. No SEC Form D was located for Granza Bio at the time of writing; that may reflect a use of the Section 4(a)(2) exemption, a filing lag, or a gap in the search rather than proof no filing exists. Healthcare Venture Capital Fund holds no position in Granza Bio. This page is not an offer to sell or a recommendation to buy any security.